ExonHit

NEW YORK (GenomeWeb News) – French biotech firm Exonhit announced today an agreement to acquire InGen BioSciences for €18 million ($23.1 million), forming a new firm called Diaxonhit.

NEW YORK (GenomeWeb News) – Exonhit today said it has been awarded €1.9 million ($2.4 million) to participate in a project aimed at developing new treatments for cancers and tools to identify patients who may be best candidates for the treatments.

An institutional review board has approved a pilot clinical trial aimed at evaluating the performance of ExonHit Therapeutics' test for Alzheimer's disease, AclarusDx.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Exonhit today announced a deal with Pfizer for use of Exonhit's technology for identifying biomarkers associated with Alzheimer's disease.

Officials from both organizations said this week that they are keen to use Exonhit's SpliceArray platform in new, sequencing-driven biomarker discovery projects.

The project combines BGI's next-generation sequencing and Exonhit's SpliceArray technologies to expand the SpliceArray platform to an additional "strategic preclinical animal model species."

Almac will run AclarusDx on the Affymetrix Dx2 platform. The test is based on Exonhit's proprietary biochip, a customized Affy GeneChip called the Genome Wide SpliceArray.

Paris-based Exonhit has already introduced AclarusDx to the French market and is planning to launch it in the wider European market.

Almac will analyze all samples performed with Exonhit's blood-based AclarusDx test.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.